Blocking a cell's protein-disposal machinery is one proposed payload strategy. A study of antibody-linked carfilzomib shows why a drug that works on its own can lose activity after delivery.
Carfilzomib was attached to antibodies against CD22 or HER2, but the resulting conjugates lost their cell-killing potency. The primary study found that lysosomal enzymes could release carfilzomib and then inactivate it. This is negative evidence for those constructs, not evidence that proteasome inhibition can never work as a payload. Intracellular chemical stability must be tested alongside release and target potency.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Showing the molecule this term concerns: Carfilzomib.
Shares Antibody-drug conjugate (ADC) and the tag failure.
Shares Antibody-drug conjugate (ADC) and the tag failure.
Shares Antibody-drug conjugate (ADC) and the tag failure.
Shares Antibody-drug conjugate (ADC) and the tag failure.
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/